Skip to main content

FDA approves Johnson & Johnson’s nasal spray for depression as standalone treatment

Spravato is now the first-ever standalone therapy for treatment-resistant depression, and is on its way to becoming a blockbuster product.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.